Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a surprise result with important implications for cardiovascular drug research.
This unexpected outcome raises significant questions about the efficacy of emerging therapies targeting Lp(a) as a cardiovascular risk factor. The failure of pelacarsen, developed by Novartis and Ionis, suggests that merely reducing Lp(a) levels may not translate into improved clinical outcomes for patients at risk of heart disease. As the pharmaceutical industry invests heavily in novel heart medicines, this setback could prompt a reevaluation of the underlying mechanisms of Lp(a) and its role in cardiovascular health.
For B2B professionals in regulatory, QA/QC, CMC, sourcing, and portfolio management, the implications are clear: a deeper understanding of the biological pathways involved is essential to guide future research and development strategies in this emerging class of therapies.
Use the database as your supply chain compass →
